Atazanavir en el tratamiento de simplificación
Efficacy of atazanavir in simplification regimens
Laura Zamora
, José María Gatell
Autor para correspondencia
ZAMORA@clinic.ub.es
Correspondencia: Dra. L. Zamora. Servicio de Infecciones. Hospital Clínic. Villarroel,170. 08036 Barcelona. España.
Correspondencia: Dra. L. Zamora. Servicio de Infecciones. Hospital Clínic. Villarroel,170. 08036 Barcelona. España.
Servicio De Infecciones. Hospital Clínic. Barcelona. España
Leído
2414
Vecesse ha leído el artículo
1025
Total PDF
1389
Total HTML
Compartir estadísticas
array:23 [ "pii" => "S0213005X08766151" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(08)76615-1" "estado" => "S300" "fechaPublicacion" => "2008-12-01" "aid" => "76615" "copyright" => "Elsevier España S.L.. Todos los derechos reservados" "copyrightAnyo" => "2008" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2008;26 Supl 17:14-21" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1759 "formatos" => array:3 [ "EPUB" => 7 "HTML" => 1037 "PDF" => 715 ] ] "itemSiguiente" => array:18 [ "pii" => "S0213005X08766163" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(08)76616-3" "estado" => "S300" "fechaPublicacion" => "2008-12-01" "aid" => "76616" "copyright" => "Elsevier España S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2008;26 Supl 17:22-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1512 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 1081 "PDF" => 423 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Atazanavir en terapias de rescate" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "22" "paginaFinal" => "27" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Efficacy of atazanavir in rescue therapy" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Joaquín Portilla, Vicente Boix, Esperanza Merino, Sergio Reus" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Joaquín" "apellidos" => "Portilla" ] 1 => array:2 [ "nombre" => "Vicente" "apellidos" => "Boix" ] 2 => array:2 [ "nombre" => "Esperanza" "apellidos" => "Merino" ] 3 => array:2 [ "nombre" => "Sergio" "apellidos" => "Reus" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X08766163?idApp=UINPBA00004N" "url" => "/0213005X/0000002600000S17/v1_201305090109/S0213005X08766163/v1_201305090109/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0213005X0876614X" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(08)76614-X" "estado" => "S300" "fechaPublicacion" => "2008-12-01" "aid" => "76614" "copyright" => "Elsevier España S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2008;26 Supl 17:9-13" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1790 "formatos" => array:3 [ "EPUB" => 9 "HTML" => 1011 "PDF" => 770 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Eficacia de atazanavir en pacientes <span class="elsevierStyleItalic">naïve</span>" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "9" "paginaFinal" => "13" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Efficacy of atazanavir in treatment-naive patients" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Santiago Moreno, Beatriz Hernández, Fernando Dronda" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Santiago" "apellidos" => "Moreno" ] 1 => array:2 [ "nombre" => "Beatriz" "apellidos" => "Hernández" ] 2 => array:2 [ "nombre" => "Fernando" "apellidos" => "Dronda" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X0876614X?idApp=UINPBA00004N" "url" => "/0213005X/0000002600000S17/v1_201305090109/S0213005X0876614X/v1_201305090109/es/main.assets" ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Atazanavir en el tratamiento de simplificación" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "14" "paginaFinal" => "21" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Laura Zamora, José María Gatell" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Laura" "apellidos" => "Zamora" "email" => array:1 [ 0 => "ZAMORA@clinic.ub.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor1" ] ] ] 1 => array:2 [ "nombre" => "José María" "apellidos" => "Gatell" ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Servicio De Infecciones. Hospital Clínic. Barcelona. España" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "⁎" "correspondencia" => "Correspondencia: Dra. L. Zamora. Servicio de Infecciones. Hospital Clínic. Villarroel,170. 08036 Barcelona. España." ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Efficacy of atazanavir in simplification regimens" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec137554" "palabras" => array:5 [ 0 => "Atazanavir" 1 => "Inhibidores de la proteasa" 2 => "Simplificación" 3 => "Tratamiento de mantenimiento" 4 => "Tratamiento de rescate" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Key words" "identificador" => "xpalclavsec137555" "palabras" => array:5 [ 0 => "Atazanavir (ATV)" 1 => "Protease inhibitor (PI)" 2 => "Simplification" 3 => "Maintenance treatment" 4 => "Rescue treatment" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">Atazanavir es un nuevo inhibidor de la proteasa azapéptido con un perfil farmacocinético singular, que permite la administración una vez al día de sólo 2 cápsulas en combinación con otros antirretrovirales. Su potente eficacia antiviral se acompaña, además, de un perfil de tolerancia excelente y de ausencia de incrementos significativos de las concentraciones de colesterol y triglicéridos. La respuesta inmunológica y virológica obtenida con atazanavir o atazanavir/ritonavir, tanto en pacientes naive como en pacientes con fracaso virológico previo a otros inhibidores de la proteasa, es excelente. Atazanavir es un atractivo fármaco para la simplificación terapéutica. Además de mantener la supresión virológica, los pacientes que cambian de otros inhibidores de la proteasa a atazanavir presentan reducciones en el colesterol total, el colesterol unido a lipoproteínas de alta densidad (cHDL) y los triglicéridos. Datos preliminares indican también que el tratamiento de mantenimiento simplificado con atazanavir/ritonavir en monoterapia puede mantener la supresión virológica de manera eficaz en pacientes seleccionados.</p>" ] "en" => array:1 [ "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">Atazanavir is a new azapeptide protease inhibitor with a remarkable pharmacokinetic profile, which means it can be administered in only two capsules once per day in combination with other antiretrovirals. Its strong antiviral efficacy is also accompanied by an excellent tolerance profile and no significant increase in cholesterol and triglyceride levels. The immunological and virological response obtained with atazanavir or atazanavir/ritonavir, in naive patients as well as in patients with previous virological failure with other protease inhibitors, is excellent. Atazanavir is an attractive drug for therapeutic simplification. Besides maintaining virological suppression, patients who change from other PI to atazanavir experience reductions in total cholesterol, HDL cholesterol and triglycerides. Preliminary data suggest that simplified maintenance treatment with atazanavir/ritonavir in monotherapy, can effectively maintain virological suppression in selected patients.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Bibliografía" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:32 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir: new option for treatment of HIV infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "D.V. Havlir" 1 => "S.D. O’Marro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/420932" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2004" "volumen" => "38" "paginaInicial" => "1599" "paginaFinal" => "1604" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15156449" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "D.R. Goldsmith" 1 => "C.M. Perry" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Drugs" "fecha" => "2003" "volumen" => "63" "paginaInicial" => "1679" "paginaFinal" => "1693" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12904086" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guía de terapéutica antimicrobiana" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J. Mensa" 1 => "J.M. Gatell" 2 => "M.T. Jimenez de Anta" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2006" "editorial" => "Masson" "editorialLocalizacion" => "Barcelona" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir does not seem to have lipid lowering properties in patients with contolled HIV infection and normal lipids" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S. Mauss" 1 => "F. Berger" 2 => "G. Schmutz" 3 => "W.O. Richter" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "XV International Conference on AIDS" "conferencia" => "Bangkok" "serieFecha" => "2004" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lipid-lowering efficacy and safety after switching to atazanavir-ritonavirbased highly active antiretroviral therapy in patients with human immunodeficiency virus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.T. Nguyen" 1 => "S.A. Eaton" 2 => "A.M. Bain" 3 => "A.P. Rahman" 4 => "K.D. Payne" 5 => "R. Bedimo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1592/phco.28.3.323" "Revista" => array:6 [ "tituloSerie" => "Pharmacotherapy" "fecha" => "2008" "volumen" => "28" "paginaInicial" => "323" "paginaFinal" => "330" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18294112" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Colafigli" 1 => "S. Di Giambenedetto" 2 => "L. Bracciale" 3 => "E. Tamburrini" 4 => "R. Cauda" 5 => "A. De Luca" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-1293.2007.00541.x" "Revista" => array:6 [ "tituloSerie" => "HIV Med" "fecha" => "2008" "volumen" => "9" "paginaInicial" => "172" "paginaFinal" => "179" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18217998" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Improvement in hyperlipidemia following switch of antiretroviral therapy to an atazanavir- based HAART regimen: experience from the US atazanavir early access program" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "G. Thal" 1 => "M. Maa" 2 => "L. McManus" 3 => "L. Bessen" 4 => "L. Abrams" 5 => "E. Cooney" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "15th International AIDS Conference" "conferencia" => "Bangkok" "serieFecha" => "2004" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "I. Sanne" 1 => "P. Piliero" 2 => "K. Squires" 3 => "A. Thiry" 4 => "S. Schnittman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2003" "volumen" => "32" "paginaInicial" => "18" "paginaFinal" => "29" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12514410" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.L. Murphy" 1 => "I. Sanne" 2 => "P. Cahn" 3 => "P. Phanuphak" 4 => "L. Percival" 5 => "T. Kelleher" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/01.aids.0000096930.51231.5d" "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2003" "volumen" => "17" "paginaInicial" => "2603" "paginaFinal" => "2614" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14685054" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Squires" 1 => "A. Lazzarin" 2 => "J.M. Gatell" 3 => "W.G. Powderly" 4 => "V. Pokrovskiy" 5 => "J.F. Delfraissy" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2004" "volumen" => "36" "paginaInicial" => "1011" "paginaFinal" => "1019" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15247553" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "R.J. Colonno" 1 => "A. Thiry" 2 => "K. Limoli" 3 => "N. Parkin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Antimicrob Agents Chemother" "fecha" => "2003" "volumen" => "47" "paginaInicial" => "1324" "paginaFinal" => "1333" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12654666" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "P. Sista" 1 => "B. Wasikowski" 2 => "P. Lecocq" 3 => "T. Pattery" 4 => "L. Bacheler" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jcv.2008.03.023" "Revista" => array:6 [ "tituloSerie" => "J Clin Virol" "fecha" => "2008" "volumen" => "42" "paginaInicial" => "405" "paginaFinal" => "408" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18472298" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of atazanavir, with or without ritonavir, as part ofonce-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "D.R. Malan" 1 => "E. Krantz" 2 => "N. David" 3 => "V. Wirtz" 4 => "J. Hammond" 5 => "D. McGrath" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAI.0b013e31815ace6a" "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2008" "volumen" => "47" "paginaInicial" => "161" "paginaFinal" => "167" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17971713" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plustenofovir/ emtricitabine, for the initial treatment of HIV infection: 48-weekresults of ALERT" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.Y. Smith" 1 => "W.G. Weinberg" 2 => "E. Dejesus" 3 => "M.A. Fischl" 4 => "Q. Liao" 5 => "L.L. Ross" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1742-6405-5-5" "Revista" => array:5 [ "tituloSerie" => "AIDS Res Ther" "fecha" => "2008" "volumen" => "5" "paginaInicial" => "5" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18373851" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naive patients: a 48-week pilot study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Elion" 1 => "E. Dejesus" 2 => "M. Sension" 3 => "D. Berger" 4 => "W. Towner" 5 => "G. Richmond" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1310/hct0903-152" "Revista" => array:6 [ "tituloSerie" => "HIV Clin Trials" "fecha" => "2008" "volumen" => "9" "paginaInicial" => "152" "paginaFinal" => "163" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18547902" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Molina JMl, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Efficacy and safety of once-daily atazanavir/ritonavir compared to twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabinein ARV-naive HIV-1-infected subjects: the CASTLE Study, 48-week results. Boston: 15th CROI; 2008." ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Johnson" 1 => "B. Grinsztejn" 2 => "C. Rodriguez" 3 => "J. Coco" 4 => "E. DeJesus" 5 => "A. Lazzarin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2005" "volumen" => "19" "paginaInicial" => "153" "paginaFinal" => "162" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15668540" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "96-week comparison of once-daily atazanavir/ritonavir and lopinavir/ritonavir in patients with multiple virologic failures" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Jhonson" 1 => "B. Ginsztejn" 2 => "C. Rodríguez" 3 => "J. Coco" 4 => "E. DeJesus" 5 => "A. Lazzarin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/01.aids.0000216371.76689.63" "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2006" "volumen" => "20" "paginaInicial" => "711" "paginaFinal" => "718" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16514301" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir in patients with persistent viral replication despite HAART: results from the French Prospective NADIS Cohort" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Cuzin" 1 => "P. Flandre" 2 => "P. Pugliese" 3 => "C. Duvivier" 4 => "Y. Yazdanpanah" 5 => "E. Billaud" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1310/hct0903-147" "Revista" => array:6 [ "tituloSerie" => "HIV Clin Trials" "fecha" => "2008" "volumen" => "9" "paginaInicial" => "147" "paginaFinal" => "151" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18547901" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. AI424- 044" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Wood" 1 => "P. Phanuphak" 2 => "P. Cahn" 3 => "V. Pokrovskiy" 4 => "W. Rozenbaum" 5 => "G. Pantaleo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2004" "volumen" => "36" "paginaInicial" => "684" "paginaFinal" => "692" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15167287" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Gatell" 1 => "D. Salmon-Ceron" 2 => "A. Lazzarin" 3 => "E. Van Wijngaerden" 4 => "F. Antunes" 5 => "C. Leen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2007" "volumen" => "44" "paginaInicial" => "1484" "paginaFinal" => "1492" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V. Soriano" 1 => "P. Garcia-Gasco" 2 => "E. Vispo" 3 => "A. Ruiz-Sancho" 4 => "F. Blanco" 5 => "L. Martin-Carbonero" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/jac/dkm413" "Revista" => array:6 [ "tituloSerie" => "J Antimicrob Chemother" "fecha" => "2008" "volumen" => "61" "paginaInicial" => "200" "paginaFinal" => "205" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17999977" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Rodriguez-Novoa" 1 => "J. Morello" 2 => "P. Barreiro" 3 => "I. Maida" 4 => "P. Garcia-Gasción" 5 => "E. Vispo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1089/aid.2007.0276" "Revista" => array:6 [ "tituloSerie" => "AIDS Res Hum Retroviruses" "fecha" => "2008" "volumen" => "24" "paginaInicial" => "821" "paginaFinal" => "825" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18507524" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Vernazza" 1 => "S. Daneel" 2 => "V. Schiffer" 3 => "L. Decosterd" 4 => "W. Fierz" 5 => "T. Klimkait" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "AIDS" "fecha" => "2007" "volumen" => "21" "paginaInicial" => "1309" "paginaFinal" => "1315" ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S. Sahali" 1 => "M.L. Chaix" 2 => "J.F. Delfraissy" 3 => "J. Ghosn" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS Rev" "fecha" => "2008" "volumen" => "10" "paginaInicial" => "4" "paginaFinal" => "14" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18385776" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of switching from lopinavir/ to atazanavir/r in patients with virologic suppression receiving a LPV/r containing HAART: the ATAZIP study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Mallolas" 1 => "D. Podzamczer" 2 => "P. Domingo" 3 => "B. Clotet" 4 => "E. Ribera" 5 => "F. Gutierrez" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "4th IAS Conference HIV Patohogenesis, Treatment and Prevention" "conferencia" => "Sydney, Australia" "serieFecha" => "2007" ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of switching from boosted Lopinavir (LPV/r) to boosted Atazanavir (ATV/r) in patients with virologic suppression and history of previous PI failures or PI resistance mutations: Subanalysis of the ATAZIP study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Mallolas" 1 => "D. Podzamczer" 2 => "P. Domingo" 3 => "B. Clotet" 4 => "E. Ribera" 5 => "F. Gutierrez" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "EACS meeting" "conferencia" => "Madrid" "serieFecha" => "2007" ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Swindells" 1 => "G. DiRienzo" 2 => "Wilkin" 3 => "C.V. Fletcher" 4 => "D.M. Margolis" 5 => "G.D. Thal" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "JAMA" "fecha" => "2006" "volumen" => "296" "paginaInicial" => "808" "paginaFinal" => "814" ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib29" "etiqueta" => "29." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of ritonavir-boosted atazanavir (ATV/r) in experienced HIV-infected patients regarding hepatitis B/C status" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.J. Perez-Elias" 1 => "J.M. Gatell" 2 => "J. Flores" 3 => "J. Santos" 4 => "F.J. Vera" 5 => "B. Clotet" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "3rd International AIDS Conference" "conferencia" => "Rio de Janeiro, 24-27 July" "serieFecha" => "2005" ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib30" "etiqueta" => "30." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.A. Pineda" 1 => "R. Palacios" 2 => "A. Rivero" 3 => "L. Abdel-kader" 4 => "M. Márquez" 5 => "P. Cano" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Antimicrob Chemother" "fecha" => "2006" "volumen" => "57" "paginaInicial" => "1016" "paginaFinal" => "1017" ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib31" "etiqueta" => "31." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.A. Pineda" 1 => "J. Santos" 2 => "A. Rivero" 3 => "L. Abdel-Kader" 4 => "R. Palacios" 5 => "A. Camacho" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/jac/dkn045" "Revista" => array:6 [ "tituloSerie" => "J Antimicrob Chemother" "fecha" => "2008" "volumen" => "61" "paginaInicial" => "925" "paginaFinal" => "932" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18276600" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib32" "etiqueta" => "32." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Urolithiasis in HIV-positive patients treated with atazanavir" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Couzigou" 1 => "M. Daudon" 2 => "J.L. Meynard" 3 => "F. Borsa-Lebas" 4 => "D. Higueret" 5 => "L. Escaut" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/521930" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2007" "volumen" => "45" "paginaInicial" => "e105" "paginaFinal" => "e108" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17879904" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/0213005X/0000002600000S17/v1_201305090109/S0213005X08766151/v1_201305090109/es/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/0213005X/0000002600000S17/v1_201305090109/S0213005X08766151/v1_201305090109/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X08766151?idApp=UINPBA00004N" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Octubre | 5 | 1 | 6 |
| 2024 Septiembre | 9 | 5 | 14 |
| 2024 Agosto | 7 | 3 | 10 |
| 2024 Julio | 5 | 5 | 10 |
| 2024 Junio | 7 | 1 | 8 |
| 2024 Mayo | 8 | 2 | 10 |
| 2024 Abril | 10 | 3 | 13 |
| 2024 Marzo | 4 | 7 | 11 |
| 2024 Febrero | 1 | 5 | 6 |
| 2024 Enero | 10 | 2 | 12 |
| 2023 Diciembre | 9 | 6 | 15 |
| 2023 Noviembre | 2 | 9 | 11 |
| 2023 Octubre | 5 | 4 | 9 |
| 2023 Septiembre | 6 | 0 | 6 |
| 2023 Agosto | 3 | 0 | 3 |
| 2023 Julio | 4 | 4 | 8 |
| 2023 Junio | 7 | 0 | 7 |
| 2023 Mayo | 2 | 2 | 4 |
| 2023 Abril | 2 | 3 | 5 |
| 2023 Marzo | 4 | 3 | 7 |
| 2023 Febrero | 6 | 0 | 6 |
| 2023 Enero | 3 | 1 | 4 |
| 2022 Diciembre | 9 | 7 | 16 |
| 2022 Noviembre | 8 | 4 | 12 |
| 2022 Octubre | 10 | 9 | 19 |
| 2022 Septiembre | 9 | 4 | 13 |
| 2022 Agosto | 11 | 5 | 16 |
| 2022 Julio | 9 | 8 | 17 |
| 2022 Junio | 6 | 8 | 14 |
| 2022 Mayo | 10 | 8 | 18 |
| 2022 Abril | 12 | 10 | 22 |
| 2022 Marzo | 8 | 5 | 13 |
| 2022 Febrero | 6 | 3 | 9 |
| 2022 Enero | 12 | 7 | 19 |
| 2021 Diciembre | 6 | 8 | 14 |
| 2021 Noviembre | 5 | 13 | 18 |
| 2021 Octubre | 8 | 6 | 14 |
| 2021 Septiembre | 4 | 7 | 11 |
| 2021 Agosto | 13 | 7 | 20 |
| 2021 Julio | 3 | 9 | 12 |
| 2021 Junio | 4 | 7 | 11 |
| 2021 Mayo | 5 | 5 | 10 |
| 2021 Abril | 8 | 3 | 11 |
| 2021 Marzo | 16 | 17 | 33 |
| 2021 Febrero | 3 | 5 | 8 |
| 2021 Enero | 1 | 13 | 14 |
| 2020 Diciembre | 7 | 4 | 11 |
| 2020 Noviembre | 6 | 7 | 13 |
| 2020 Octubre | 2 | 2 | 4 |
| 2020 Septiembre | 6 | 7 | 13 |
| 2020 Agosto | 6 | 9 | 15 |
| 2020 Julio | 6 | 12 | 18 |
| 2020 Junio | 3 | 3 | 6 |
| 2020 Mayo | 6 | 12 | 18 |
| 2020 Abril | 1 | 1 | 2 |
| 2020 Marzo | 4 | 9 | 13 |
| 2020 Febrero | 1 | 4 | 5 |
| 2020 Enero | 1 | 2 | 3 |
| 2019 Diciembre | 4 | 6 | 10 |
| 2019 Noviembre | 3 | 2 | 5 |
| 2019 Octubre | 1 | 1 | 2 |
| 2019 Septiembre | 5 | 4 | 9 |
| 2019 Agosto | 1 | 6 | 7 |
| 2019 Julio | 3 | 16 | 19 |
| 2019 Junio | 24 | 14 | 38 |
| 2019 Mayo | 61 | 44 | 105 |
| 2019 Abril | 17 | 39 | 56 |
| 2019 Marzo | 0 | 11 | 11 |
| 2019 Febrero | 2 | 27 | 29 |
| 2019 Enero | 2 | 10 | 12 |
| 2018 Diciembre | 0 | 4 | 4 |
| 2018 Noviembre | 3 | 7 | 10 |
| 2018 Octubre | 3 | 5 | 8 |
| 2018 Septiembre | 2 | 6 | 8 |
| 2018 Agosto | 1 | 21 | 22 |
| 2018 Julio | 4 | 8 | 12 |
| 2018 Junio | 1 | 7 | 8 |
| 2018 Mayo | 3 | 14 | 17 |
| 2018 Abril | 2 | 16 | 18 |
| 2018 Marzo | 1 | 2 | 3 |
| 2018 Febrero | 0 | 6 | 6 |
| 2018 Enero | 1 | 3 | 4 |
| 2017 Diciembre | 3 | 2 | 5 |
| 2017 Noviembre | 3 | 5 | 8 |
| 2017 Octubre | 2 | 11 | 13 |
| 2017 Septiembre | 3 | 7 | 10 |
| 2017 Agosto | 4 | 6 | 10 |
| 2017 Julio | 3 | 14 | 17 |
| 2017 Junio | 4 | 13 | 17 |
| 2017 Mayo | 12 | 13 | 25 |
| 2017 Abril | 6 | 3 | 9 |
| 2017 Marzo | 13 | 18 | 31 |
| 2017 Febrero | 4 | 4 | 8 |
| 2017 Enero | 2 | 0 | 2 |
| 2016 Diciembre | 2 | 0 | 2 |
| 2016 Noviembre | 3 | 3 | 6 |
| 2016 Octubre | 15 | 3 | 18 |
| 2016 Septiembre | 5 | 1 | 6 |
| 2016 Agosto | 5 | 0 | 5 |
| 2016 Julio | 8 | 1 | 9 |
| 2016 Junio | 13 | 10 | 23 |
| 2016 Mayo | 25 | 15 | 40 |
| 2016 Abril | 16 | 33 | 49 |
| 2016 Marzo | 13 | 17 | 30 |
| 2016 Febrero | 10 | 22 | 32 |
| 2016 Enero | 6 | 25 | 31 |
| 2015 Diciembre | 9 | 22 | 31 |
| 2015 Noviembre | 18 | 18 | 36 |
| 2015 Octubre | 11 | 19 | 30 |
| 2015 Septiembre | 9 | 14 | 23 |
| 2015 Agosto | 12 | 11 | 23 |
| 2015 Julio | 8 | 12 | 20 |
| 2015 Junio | 6 | 8 | 14 |
| 2015 Mayo | 6 | 1 | 7 |
| 2015 Abril | 9 | 8 | 17 |
| 2015 Marzo | 7 | 2 | 9 |
| 2015 Febrero | 7 | 10 | 17 |
| 2015 Enero | 16 | 4 | 20 |
| 2014 Diciembre | 20 | 8 | 28 |
| 2014 Noviembre | 21 | 4 | 25 |
| 2014 Octubre | 28 | 5 | 33 |
| 2014 Septiembre | 16 | 2 | 18 |
| 2014 Agosto | 28 | 1 | 29 |
| 2014 Julio | 25 | 0 | 25 |
| 2014 Junio | 22 | 2 | 24 |
| 2014 Mayo | 11 | 1 | 12 |
| 2014 Abril | 14 | 3 | 17 |
| 2014 Marzo | 11 | 1 | 12 |
| 2014 Febrero | 17 | 1 | 18 |
| 2014 Enero | 15 | 1 | 16 |
| 2013 Diciembre | 16 | 5 | 21 |
| 2013 Noviembre | 15 | 4 | 19 |
| 2013 Octubre | 16 | 9 | 25 |
| 2013 Septiembre | 13 | 12 | 25 |
| 2013 Agosto | 15 | 14 | 29 |
| 2013 Julio | 10 | 2 | 12 |
| 2008 Diciembre | 280 | 0 | 280 |
Mostrar todo
